---
document_datetime: 2025-02-26 14:57:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/kostaive-epar-all-authorised-presentations_en.pdf
document_name: kostaive-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7022605
conversion_datetime: 2025-12-30 07:44:34.967538
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                 | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                      |
|------------------|-------------------|------------|-------------------------------------|---------------------------|-----------------------|---------------------------|--------------------------------|
| EU/1/24/1873/001 | Kostaive          | --ยน        | Powder for dispersion for injection | Intramuscular use         | vial (glass)          | 16 doses                  | 20 multidose vials (320 doses) |

--ยน

After reconstitution with 10 mL of sterile 0.9% Sodium Chloride Injection, one dose (0.5 mL) contains 5 micrograms of Zapomeran, a COVID-19 mRNA (encapsulated in lipid nanoparticles).

Zapomeran is a single-stranded, 5'-capped messenger RNA (mRNA) replicon (self-amplifying mRNA), produced using a cell-free in vitro transcription from the corresponding DNA templates encoding a replicase and the spike glycoprotein of the G clade D614G variant of SARS-CoV-2.